<font color="blue">Assessment_2</font> <font color="blue">of_1</font> <font color="blue">acute_2</font> <font color="blue">bronchodilator_2</font> <font color="blue">effects_2</font> <font color="blue">from_1</font> <font color="blue">specific_3</font> <font color="blue">airway_3</font> <font color="blue">resistance_3</font> <font color="blue">changes_2</font> in stable COPD patients . 
<br>
<br> BACKGROUND In COPD patients , reversibility is currently evaluated from the changes of <font color="blue">forced_2</font> <font color="blue">expiratory_2</font> <font color="blue">volume_2</font> <font color="blue">at_1</font> <font color="blue">1s_1</font> <font color="blue">(_1</font> <font color="blue">ΔFEV1_1</font> <font color="blue">)_1</font> and <font color="blue">forced_1</font> <font color="blue">vital_1</font> <font color="blue">capacity_1</font> <font color="blue">(_1</font> <font color="blue">ΔFVC_1</font> <font color="blue">)_1</font> <font color="blue">._1</font> By <font color="blue">lowering_1</font> <font color="blue">peripheral_1</font> <font color="blue">airway_1</font> smooth muscle tone , bronchodilators should <font color="blue">decrease_1</font> <font color="blue">dynamic_2</font> <font color="blue">hyperinflation_2</font> <font color="blue">,_2</font> <font color="blue">gas_2</font> <font color="blue">trapping_2</font> <font color="blue">,_2</font> <font color="blue">and_2</font> <font color="blue">possibly_2</font> <font color="blue">dyspnea_2</font> <font color="blue">at_1</font> <font color="blue">rest_1</font> <font color="blue">._1</font> Hence , we hypothesize that <font color="blue">specific_1</font> <font color="blue">airway_1</font> <font color="blue">resistance_1</font> <font color="blue">changes_1</font> <font color="blue">(_1</font> <font color="blue">ΔsRAW_1</font> <font color="blue">)_1</font> should better characterize the <font color="blue">acute_1</font> <font color="blue">response_1</font> <font color="blue">to_1</font> <font color="blue">bronchodilators_1</font> <font color="blue">._1</font> 
<br> METHODS On two days , 60 COPD patients underwent <font color="blue">dyspnea_2</font> <font color="blue">evaluation_2</font> <font color="blue">(_2</font> <font color="blue">VAS_2</font> <font color="blue">score_2</font> <font color="blue">)_2</font> <font color="blue">and_1</font> <font color="blue">pulmonary_2</font> <font color="blue">function_2</font> <font color="blue">testing_1</font> at baseline and one hour after placebo or 300μg indacaterol administration . 
<br> RESULTS <font color="blue">Spirographic_4</font> <font color="blue">and_4</font> <font color="blue">ΔsRAW_4</font> <font color="blue">-_4</font> <font color="blue">based_4</font> <font color="blue">criteria_4</font> <font color="blue">identified_1</font> <font color="blue">as_1</font> <font color="blue">responders_1</font> 24 and 45 patients , respectively . <font color="blue">ΔsRAW_3</font> correlated with changes of <font color="blue">intrathoracic_4</font> <font color="blue">gas_4</font> <font color="blue">volume_4</font> <font color="blue">(_1</font> <font color="blue">ΔITGV_1</font> <font color="blue">)_1</font> ( r=0.61 ; p<0.001 ) , <font color="blue">residual_5</font> <font color="blue">volume_5</font> <font color="blue">(_1</font> <font color="blue">ΔRV_2</font> <font color="blue">)_2</font> ( r=0.60 ; p<0.001 ) , <font color="blue">ΔFVC_3</font> ( r=0.44 ; p=0.001 ) , and <font color="blue">ΔVAS_2</font> ( r=0.73 ; p<0.001 ) , while <font color="blue">ΔFEV1_3</font> correlated only with <font color="blue">ΔFVC_3</font> ( r=0.34 ; p=0.008 ) . Significant differences in terms of <font color="blue">ΔITGV_3</font> <font color="blue">(_1</font> <font color="blue">p=0.002_1</font> <font color="blue">)_1</font> <font color="blue">,_1</font> <font color="blue">ΔRV_3</font> <font color="blue">(_1</font> <font color="blue">p=0.023_1</font> <font color="blue">)_1</font> <font color="blue">,_1</font> <font color="blue">and_1</font> <font color="blue">ΔVAS_3</font> ( p<0.001 ) occurred only if patients were stratified according to <font color="blue">ΔsRAW_2</font> <font color="blue">._2</font> 
<br> CONCLUSIONS In assessing the <font color="blue">acute_1</font> <font color="blue">functional_2</font> <font color="blue">effect_2</font> <font color="blue">of_2</font> <font color="blue">bronchodilators_2</font> <font color="blue">,_2</font> <font color="blue">ΔsRAW_2</font> <font color="blue">-_2</font> <font color="blue">based_1</font> <font color="blue">criterion_1</font> is preferable to <font color="blue">FEV1-FVC_3</font> <font color="blue">-_2</font> <font color="blue">based_1</font> <font color="blue">criteria_1</font> <font color="blue">,_1</font> being more closely related to <font color="blue">bronchodilator_2</font> <font color="blue">-_2</font> <font color="blue">induced_2</font> <font color="blue">improvements_2</font> <font color="blue">of_1</font> <font color="blue">lung_1</font> <font color="blue">mechanics_1</font> <font color="blue">and_1</font> <font color="blue">dyspnea_1</font> at rest .